Kodiak Sciences Inc.
- KOD
- NASDAQ
- Biotechnology
- Retinal Disease Therapies
- Anti-VEGF Biologics (KSI-301)
$90.49
Today +5.53%Quote Oct 19, 2026, 04:10 PM UTC
+161.04%over the last month
Max drawdown −18.8%From 1-month high −14.1%3 months +109.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Kodiak Sciences
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
141
Market value
$5.69B
Quote Oct 19
Floor
$89.54
1.0% below price
Resistance
$91.52
1.1% above price
Price vs analyst targets
19 analysts
Lowest target
$61.00Highest target
$126.00
$61.00Highest target
$126.00
- Price $90.49
- Average target $104.40
- Analysts' target range
Analysts' average target sits about 15% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KODPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free